WHO ICTRP trial
Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment…
EUCTR2009-016926-15-IT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2009-016926-15-IT |
|---|---|
| Public title | Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment for Coroidal Neovascularization (CNV) secondary to exudative Age Related Macular Degeneration (AMD) - OFT-09-01 |
| Scientific title | Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment for Coroidal Neovascularization (CNV) secondary to exudative Age Related Macular Degeneration (AMD) - OFT-09-01 |
| Primary sponsor | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | exudative Age Related Macular Degeneration MedDRA version: 12.1 Level: LLT Classification code 10015902 Term: Exudative senile macular degeneration of retina |
| Interventions | Trade Name: AVASTIN Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Bevacizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- |
| Registration date | Mar 23, 2010 |
| Secondary IDs | OFT-09-01 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: